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Abstract: Feline hepatic lipidosis (HL), the most common hepatobiliary disease in cats, is characterized by the 
accumulation of excessive triglycerides (TGs) in more than 80% of hepatocytes. Forced oral feeding is recom-
mended as the only therapy for this disease but the prognosis is often poor. As human placenta extract (Laennec) 
has been used to improve hepatic metabolism, we investigated the efficacy of this drug for the treatment of cats 
with HL. Ten cats diagnosed with HL in this study were treated with Laennec as a therapeutic drug. An im-
mediate improvement in clinical symptoms was observed in all 10 cases. A statistical analysis indicated that the 
blood level of ALT (P = 0.029), AST (P = 0.029), ALP (P = 0.005), and T-Bil (P = 0.012) decreased significantly 
after treatment. All 7 hospitalized cases were eventually discharged from the hospital with a mean hospitaliza-
tion duration of 4.8 days. The results of this study suggest that Laennec preparation has potential as an effective 
medicine for feline HL.
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I  Introduction
Feline hepatic lipidosis (HL) is characterized by severe 
triglyceride accumulation in hepatocytes, causing cholesta-
sis and liver disorders1-4). The triglyceride content in the 
liver tissue of cats with lipidosis averaged 43% compared 
to 10% in that of healthy cats1-4). HL is a secondary disorder 
concurrent with other essential diseases; more than 90% 
of lipidosis cases also had small intestinal diseases, pan-
creatitis, neoplasia, kidney disease, or diabetes mellitus1-5). 
Therefore, it is very important to treat the underlying 
disease. Refeeding syndrome is characterized by severe 
hypophosphatemia that occurs in patients given enteral or 
parenteral nutrition6). Therefore, even if treatment of the 
underlying disease was successful and only HL remained, 
the treatment period may be extended over the long-term. 
According to a specific report, in the absence of a diagnosis 
of a fatal underlying condition, recovery rates of 80%–88% 
could be expected if enteral feeding was initiated early 
in the course of the disease and sustained until voluntary 
intake resumed. However, cats might need tube feeding for 
several (3–6) weeks, requiring the owner to be an active 
participant in the recovery of their pet7, 8). Forced oral 
feeding is of limited benefit in cats that have been anorectic 
for prolonged periods and can be stressful when performed 
as long-term hospital care. At present, there are no reports 
on an effective medical therapy for fatty degeneration of 
hepatocytes. Human placenta extract (Laennec; JAPAN 
BIO PRODUCTS Co., Ltd., Tokyo, Japan) contains HGF, 
a hepatocyte growth factor that has a number of positive 
effects: (1) promoting liver regeneration, (2) promoting 
hepatocyte DNA synthesis, (3) preventing liver damage, 
(4) anti-fat liver, and (5) preventing liver fibroplasia9-11). In 
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this report, Laennec was administrated to 10 cats with HL 
as an adjunct therapy during the treatment of an underlying 
disease with conventional nourishment therapy. 
II  Materials and Methods
A diagnosis of HL was based on a compatible history, 
clinical symptoms, biochemical and sonographic findings, 
plus the cytology of a fine needle liver biopsy5, 12–18). The 
findings of cytological examination showed a vacuolation 
in the majority of sampled hepatocytes in all 10 cats (Fig. 
1). In addition, all 10 cats had underlying diseases; acute 
pancreatitis (Case 1), inflammatory bowel disease (IBD) 
(Cases 2 and 10), immune-mediated neutropenia and 
thrombocytopenia (IMNP/IMTP) (Case 3), diabetic keto-
acidosis/acute pancreatitis (Cases 4 and 7), gastrointestinal 
low-grade lymphoma (Case 5), IBD/acute pancreatitis (Case 
6), feline infectious peritonitis (FIP) dry type (Case 8), and 
FIP wet type (Case 9). These 10 cases were diagnosed with 
HL at a private veterinary hospital (AKIYOSHI ANIMAL 
CLINIC [author’s] between April 2013 and March 2015.
On the day that HL was diagnosed, Laennec (2 ml/
head; Laennec contains a water-soluble agent of the human 
placenta extract resolvent 112 mg out of 2 ml of 1 ampoule) 
was subcutaneously administered to all cats undergoing 
forced oral feeding and treatment for the underlying disease. 
All procedures in this study were performed in accordance 
with the Animal Protection Guidelines of Azabu University 
(authorization no. 1707019). This study, using client-owned 
cats, demonstrates a best practice of veterinary therapy and 
involves informed client consent.
For the seven cases of hospitalized cats, Laennec was 
administered every day until discharge. For the remaining 
three ambulatory cases, Laennec was injected from days 
3 to 7.  Physical examination, the time taken to recover 
appetite, and a complete blood workup and blood chemistry 
that included alanine transaminase (ALT), aspartate amino-
transferase (AST), alkaline phosphatase (ALP), γ-glutamyl 
transferase (GGT), total bilirubin (T-Bil), total cholesterol 
(T-cho), total protein (TP), albumin (Alb), blood urea nitro-
gen (BUN), creatinine (Cre), calcium (Ca), phosphorus (P), 
glucose (Glu), triglycerides (TG), and electrolytes (Na, K, 
Cl) were investigated. Table 1 summarizes the  information 
on the concurrent disease, treatment, prognosis and number 
of Laennec injection in the 10 cats.
Fig. 1 Cytology findings of hepatic lipidosis.
Hepatocytes showed intense vacuolation. The sample was collected by fine 
needle biopsy (Case 2; Wright’s Giemsa Staining, × 1,000).
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III  Results and Discussion
The median pre-treatment ALT, AST, ALP, and T-Bil 
values were 453 U/l, 279 U/l, 198 U/l, and 1.1 mg/dl, 
respectively. The median post-treatment ALT, AST, ALP, 
and T-Bil values were 151 U/l, 73 U/l, 90 U/l, and 0.5 mg/dl, 
respectively. (Fig. 2)  The degree of decreased liver enzyme 
levels (ALT, AST, and ALP) and T-Bil varied, but a prompt 
improvement was confirmed by an alleviation of symptoms 
in all cases. Table 2 shows the transition of blood test results 
of 10 cases.  A statistical analysis included a Wilcoxon 
signed-rank test using EXCEL (Microsoft, Washington, 
U.S.A.) and STATMATE (Nihon 3B Scientific, Nigata, 
Japan). Statistical analysis indicated that ALT (P = 0.029), 
AST (P = 0.029), ALP (P = 0.005), and T-Bil (P = 0.012) 
decreased significantly after treatment (P value<0.05). All 
cases were eventually discharged with a mean hospitaliza-
tion duration of 4.8 days.
This report demonstrated the therapeutic potential of a 
Laennec preparation as an effective medicine to treat Feline 
HL. A decrease in ALT levels was seen in all cases and the 
mean time taken for appetite improvement was 4.8 days, 
Fig. 2 Changes in blood chemistry.
The boxplot of ALT (dark gray), AST (light gray), ALP (middle gray) and T-Bil (white) levels of 10 
cases, pre- and post- Laennec injection. The cross shows the mean and the bar shows the median. 
The values of ALT, AST, ALP, T-Bil were statistically compared between pre-treatment (pre) and 
post-treatment (post) values. The asterisk shows a significant difference (P< 0.05) in statistics.
Table 2 The transition of blood test results of 10 cases.
Pre shows the value of the blood test before Laennec injection and Post shows the value of the blood test at the time of completion 
of Laennec injection. NA means that Laennec injection was administrated by going to hospital for tratment
ALT Pre ALT Post AST Pre AST Post ALP Pre ALP Post T-Bil Pre T-Bil Post Hospitalization
Case 1 524 U/l 425 U/l 410 U/l 39 U/l 319 U/l 72 U/l 0.8 mg/dl 0.3 mg/dl NA
Case 2 907 U/l 545 U/l 401 U/l 258 U/l 932 U/l 1159 U/l 4.9 mg/dl 1.1 mg/dl 7days
Case 3 1318 U/l 159 U/l 229 U/l 32 U/l 657 U/l 253 U/l 0.6 mg/dl 0.4 mg/dl NA
Case 4 428 U/l 142 U/l 279 U/l 73 U/l 112 U/l 80 U/l 0.5 mg/dl 0.3 mg/dl 5days
Case 5 1132 U/l 95 U/l NA NA 215 U/l 172 U/l 0.09 mg/dl 0.1 mg/dl NA
Case6 266 U/l 123 U/l 512 U/l 41 U/l 83 U/l 68 U/l 1.3 mg/dl 0.6 mg/dl 3days
Case7 352 U/l 273 U/l 208 U/l 275 U/l 49 U/l 90 U/l 1.5 mg/dl 0.6 mg/dl 3days
Case8 477 U/l 176 U/l 239 U/l 64 U/l 180 U/l 58 U/l 0.8 mg/dl 0.2 mg/dl 4days
Case9 269 U/l 141 U/l 639 U/l 514 U/l 121 U/l 90 U/l 3.9 mg/dl 3.3 mg/dl 5days
Case10 372 U/l 132 U/l 136 U/l 129 U/l 809 U/l 350 U/l 2.2 mg/dl 0.6 mg/dl 7days
Reference range: ALT: 20–84U/l, AST: 12–45U/l, ALP: 26–160U/l, T-Bil: 0–0.7mg/dl.
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which was dramatically shorter than that presented in other 
reports7, 8). Furthermore, the ratio of decreased liver enzyme 
(ALT, AST, ALP) went along with hospitalization days for 
time to appetite improvement and the average hospitaliza-
tion days of the non-administrated group was 12.0 days in 
our hospital. (Akiyoshi, M. and Hisasue, M., unpublished 
results) A particularly remarkable effect was seen in Case 
1. This cat had acute pancreatitis and developed HL several 
times in the past, always necessitating hospitalization for 
10 to 14 days. However, the symptoms and hepatic enzyme 
abnormalities of HL in this cat improved following a 
single injection of Laennec with conventional treatment 
and hospitalization management, and forced feeding was 
not required. HL and pancreatitis recurred 5 times over the 
following 2 years, and each time the cat was given Laennec 
recovery was evident by day 3. Furthermore, in HL cases 
with IBD or acute pancreatitis (Cases 2, 4, 6, 7, and 10), 
the length of hospitalization was less than 1 week, and it 
was suggested that the Laennec injection was more effec-
tive than the previously reported treatment in which tube 
feeding was necessary for 3–6 weeks7,8). In this study, the 
therapeutic dose of Laennec was extrapolated with reference 
to the therapeutic dose in humans19). The determination of 
a concrete therapeutic dose will be necessary in the future.
In this report, no side effects of a Laennec injection were 
seen in all cases. The maximum number of Laennec injec-
tions given to an individual cat in this study was seven (Cases 
2 and 10), and no abnormalities were detected by physical 
examination. In human clinical trials, side effects were 
reported in 3.7% of 237 patients. The main side effects were 
pain at the injection site (2.56%), hypersensitivity (0.37%), 
and induration of the injection site (0.37%)19). Laennec was 
extracted from human placental tissue and is an exogenous 
material for cats. An increased risk of hypersensitivity and 
anaphylaxis was thus presumed to occur in cats compared 
to human patients. As such, careful follow up of the treated 
cats is required.
There were three problems in this study. The first problem 
was variability in the underlying disease of the 10 cases. The 
second problem was that there was no comparison with a 
control group that was not given Laennec. The third problem 
was that a definitive diagnosis of HL was not completed. We 
were unable to exclude other hepatobiliary diseases such as 
inflammatory, neoplastic, and blood vessel dysplasia since 
open wedge liver biopsies were not conducted. Therefore, 
it will be necessary to solve these problems in the future 
to prove the effect of a Laennec injection treatment for 
feline HL. It was suggested that enforcing an evaluation 
by unifying the underlying diseases, comparing a Laennec 
injection group with a non-administered group, and a 
histopathological examination of the liver will be necessary 
for further confirmation of the efficacy of Laennec.
In this study, clinical symptoms and liver enzyme levels in 
all cats with HL recovered following a treatment of Laennec 
injections with a mean hospitalization duration of only 4.8 
days. A Laennec injection will be expected to reduce the cost 
and term of hospitalization and may contribute to improved 
feline HL outcomes. Further investigations that include a 
prospective study are necessary to determine the efficacy 
of Laennec.
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